TXA 302

Drug Profile

TXA 302

Alternative Names: TXA-302

Latest Information Update: 02 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TarixCVM
  • Developer Constant Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Metabolic disorders; Stroke

Most Recent Events

  • 06 Mar 2018 Constant Pharmaceuticals plans a phase II trial for Stroke in 2019
  • 06 Mar 2018 TXA 302 has patent protection in Japan and USA
  • 03 Aug 2016 Preclinical trials in Cardiovascular disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top